07-15-2010: Intana Bioscience GmbH announced that it has entered an agreement with Johnson & Johnson Pharmaceutical Research & Development, a division of Janssen Pharmaceutica N.V., Beerse, Belgium. Under the agreement, Intana will provide its proprietary Fluorescent Cross Correlation Spectroscopy (FCCS) technology platform to screen for small molecule inhibitors of a set of target proteins.
FCCS is a spectroscopic method to measure the interactions of molecules in solution, based on the sensitive detection of single molecules. The proprietary technology of Intana Bioscience allows FCCS to be performed in cellular lysates, thereby characterizing the interactions between small molecules and their target proteins in approximately physiological conditions. In the course of this collaboration, Intana will develop assays and establish a medium to high throughput screening platform for drug discovery projects at Janssen Pharmaceutica N.V. Additionally the technology will provide access to the binding kinetics of identified inhibitors, in support of lead optimization.
Chemical alterations of the genetic information specifically occuring during carcinogenesis provide the basis for the innovative diagnostic tests that are developed by the newly established oncgnostics GmbH in Jena. These tests allow not only for an earlier, but also a more accurate detecti ... more
SAW Instruments has completed in early February its second financing round of one million EUR and is aiming to reach break-even in fiscal year 2012. “The funds will be invested in particular in the expansion of sales & marketing activities and extending our product portfolio.” says Mana ... more
PEPperPRINT has won German Industry’s Innovation Award 2010 in the startup category. The biotech company from Heidelberg, Germany, was awarded in line of 30th German Industry’s Gala at the Congress Center Frankfurt by Federal Minister of Education and Research, Dr. Annette Schavan.
PEPp ... more
Cenix BioScience GmbH announced that, together with its new subsidiary, Cenix BioScience Belgium bvba, it has signed a Collaboration and Technology License Agreement with Janssen Research & Development, a division of Janssen Pharmaceutica NV, to improve the in vivo applicability of siRNA-ba ... more
Intana Bioscience GmbH announced that it has entered an agreement with Johnson & Johnson Pharmaceutical Research & Development, a division of Janssen Pharmaceutica N.V., Beerse, Belgium. Under the agreement, Intana will provide its proprietary Fluorescent Cross Correlation Spectroscopy (FCC ... more
Intana Bioscience GmbH announced that it has entered an agreement with Johnson & Johnson Pharmaceutical Research & Development, a division of Janssen Pharmaceutica N.V., Beerse, Belgium. Under the agreement, Intana will provide its proprietary Fluorescent Cross Correlation Spectroscopy (FCC ... more
Intana Bioscience GmbH announced that it has entered an agreement with Johnson & Johnson Pharmaceutical Research & Development, a division of Janssen Pharmaceutica N.V., Beerse, Belgium. Under the agreement, Intana will provide its proprietary Fluorescent Cross Correlation Spectroscopy (FCC ... more
Intana Bioscience GmbH announced that it has entered an agreement with Johnson & Johnson Pharmaceutical Research & Development, a division of Janssen Pharmaceutica N.V., Beerse, Belgium. Under the agreement, Intana will provide its proprietary Fluorescent Cross Correlation Spectroscopy (FCC ... more